PICO Portalanswers from OpenAlex & ORCID
Esther Holgado
ResearcherPublications, citations & collaboration network
Esther Holgado is a researcher indexed in PICO Portal from OpenAlex & ORCID.
How many works does Esther Holgado have?
PICO Portalindexed works
Esther Holgado has 84 works in the PICO Portal index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Esther Holgado have?
PICO Portalcitation count
Esther Holgado has 24,551 citations in the OpenAlex counts PICO Portal stores.
What is the h-index of Esther Holgado?
PICO Portalh-index
Esther Holgado has an h-index of 24 in OpenAlex.
What is the i10-index of Esther Holgado?
PICO Portali10-index
Esther Holgado has an i10-index of 35 in OpenAlex.
What is the ORCID of Esther Holgado?
PICO Portalorcid
The ORCID for Esther Holgado is on the source record.
What is the OpenAlex record for Esther Holgado?
PICO Portalopenalex
The OpenAlex for Esther Holgado is on the source record.
What are the most-cited papers on Esther Holgado?
PICO Portalmost cited works
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
H. Borghaei, L. Paz-Ares, Leora Horn, David R. Spigel, Martin Steins, Neal Ready, Laura Q.M. Chow, Everett E. Vokes, Enriqueta Felip, Esther Holgado, Fabrice Barlési, Martin Kohlhäufl, Óscar Arrieta, M. Burgio, Jérôme Fayette, H. Lena, Elena Poddubskaya, David E. Gerber, Scott Gettinger, Charles M. Rudin, Naiyer A. Rizvi, Lucio Crinò, George R. Blumenschein, Scott Antonia, Cécile Dorange, Christopher Harbison, F. Graf Finckenstein, Julie R. Brahmer
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Julie R. Brahmer, Karen L. Reckamp, Paul Baas, Lucio Crinò, Wilfried Eberhardt, Elena Poddubskaya, Scott Antonia, Adam Płużański, Everett E. Vokes, Esther Holgado, David Waterhouse, Neal Ready, Justin F. Gainor, Osvaldo Arén Frontera, Libor Havel, Martin Steins, Marina Chiara Garassino, Joachim G.J.V. Aerts, Manuel Dómine, Luis Paz‐Ares, Martin Reck, Christine Baudelet, Christopher Harbison, Brian Lestini, David R. Spigel
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)
Leora Horn, David R. Spigel, Everett E. Vokes, Esther Holgado, Neal Ready, Martin Steins, Elena Poddubskaya, Hossein Borghaei, Enriqueta Felip, Luis Paz‐Ares, Adam Płużański, Karen L. Reckamp, Marco Angelo Burgio, Martin Kohlhäeufl, David Waterhouse, Fabrice Barlési, Scott Antonia, Óscar Arrieta, Jérôme Fayette, Lucio Crinò, Naiyer A. Rizvi, Martin Reck, Matthew D. Hellmann, William J. Geese, Ang Li, Anne Blackwood‐Chirchir, Diane Healey, Julie R. Brahmer, Wilfried Eberhardt